Prolonged postoperative euglycemic diabetic ketoacidosis in a lung transplant recipient with preoperative SGLT2 inhibitor use

Sodium-glucose cotransporter-2 (SGLT2) inhibitors were first approved by the Food& Drug Administration (FDA) in 2013 as a therapy to improve glycemic control in patients with type 2 diabetes mellitus (T2DM)1. With recent evidence suggesting decreased risk of death from cardiovascular causes as well as cardio- and renal-protective effects,2-10 the indications for SGLT2 inhibitor use have expanded to include patients with cardiovascular disease, systolic and diastolic heart failure, chronic kidney disease,11,12 as well as patients hospitalized for acute de novo or decompensated chronic heart failure, regardless of ejection fraction or concurrent diagnosis of T2DM after initial stabilization.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Case Report Source Type: research